Whole-genome sequencing, which looks at a bigger genetic picture than targeted gene panels, is offering new hope for the 3% of infants born with rare genetic diseases; there are a growing number of patients taking specialty drugs being hit with sticker shock as they find their expensive medications are no longer shielded by co-pay assistance programs; veterans groups are praising the nomination of Robert Wilkie to lead the Department of Veterans Affairs (VA) as a stabilizing next step for the troubled agency.
Whole-genome sequencing, which looks at a bigger genetic picture than targeted gene panels, is offering new hope for the 3% of infants born with rare genetic diseases, The Wall Street Journal reported. Neonatal physicians may be able to make diagnoses that once took weeks or months, often at great expense, in a matter of days, allowing for treatment to begin sooner.There are a growing number of patients taking specialty drugs being hit with sticker shock as they find their expensive medications are no longer shielded by co-pay assistance programs that help cover their costs, Kaiser Health News reported. Kaiser profiled a woman whose multiple sclerosis drug cost $90,000 and the change means that the pharmaceutical company’s co-pay assistance no longer counts towards her $8800 pharmacy deductible. In these programs, consumers typically owe nothing or have modest monthly co-payments for pricey drugs because many manufacturers pay a patient’s portion of the cost to the insurer.
Veterans groups are praising the nomination of Robert Wilkie to lead the Department of Veterans Affairs (VA) as a stabilizing next step for the troubled agency, The Hill reported. Wilkie, who is serving as acting VA secretary, is drawing bipartisan praise. He has years of Capitol Hill and Pentagon experience, has worked for 2 presidents, and has drawn praise from both Republicans and Democrats. The nomination is seen as a safe choice in the aftermath of the failed nomination of former White House physician Ronny Jackson.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More